Novel oral anticoagulants and the 73rd anniversary of historical warfarin
Jan 01, 2016
DOI: 10.1016/j.jsha.2015.05.003
Published in: Journal of the Saudi Heart Association
Publisher: Journal of the Saudi Heart Association
‘The can of un-coagulated blood lying on the floor of Link’s laboratory was to change the course of history, and little did Link know what the long-term implications would be’’[1]. In 1941, the Wisconsin Alumni Research Fund (WARF) scientist Karl Paul Link and his senior student Wilhelm Schoeffel could never have imagined that their research would live longer than 73 years. Link named the substance after the organization that supported his research and the name warfarin was created (Fig. 1). In the 1950s, warfarin was used as an anticoagulant for victims of heart attacks and strokes. It gained fame when it was used to treat President Dwight D. Eisenhower after his 1955 coronary event while in office [1]. The historical narrative of warfarin starts with a mysterious hemorrhagic disease (sweet clover disease) of cattle to the development of a rat poison (rodenticide), which later became one of the most commonly
Other Researches
Autistic Spectrum Disorder (ASD) is a complex neurodevelopmental brain disorder characterized by two core behavioral symptoms, namely impairments in social communication and restricted/repetitive behavior. The molecular mechanisms underlying ASD are...
Current Enlightenment About Etiology and Pharmacological Treatment of Autism Spectrum Disorder
Autistic Spectrum Disorder (ASD) is a complex neurodevelopmental brain disorder characterized by two core behavioral symptoms, namely impairments in social communication and restricted/repetitive behavior. The molecular mechanisms underlying ASD are...
Histamine H3 receptor as a potential target for cognitive symptoms in neuropsychiatric diseases
The potential contributions of the brain histaminergic system in neurodegenerative diseases, and the possiblity of histamine-targeting treatments is attracting considerable interests. The histamine H3 receptor (H3R) is expressed mainly in the centra...
Clinical utility of dabigatran in United Arab Emirates: A pharmacovigilance study
Objectives: To provide early data regarding clinical utility of dabigatran in Al-Ain, United Arab Emirates (UAE). Methods: This was an ethics approved retrospective cross sectional study. We retrieved a total of 76 patients who were using dabig...
Pharmaceutical care of patients with heart failure
Aim The aim of this study was to investigate the impact of a pharmacist-led pharmaceutical care programme, involving optimization of drug treatment and intensive education and self-monitoring of patients with heart failure (HF) within the United Ar...